Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jul 14;66(1):2500446.
doi: 10.1183/13993003.00446-2025. Print 2025 Jul.

How to treat patients with MDA5-associated rapidly progressive interstitial lung disease? Which immunosuppressive therapy for which patients?

Yurdagül Uzunhan  1 , Baptiste Hervier  2
Affiliations
Comment

How to treat patients with MDA5-associated rapidly progressive interstitial lung disease? Which immunosuppressive therapy for which patients?

Yurdagül Uzunhan et al. Eur Respir J. .

Abstract

The question is whether tofacitinib (TOF) is more effective than calcineurin inhibitors (CNIs) in all forms of MDA5-ILD and, more importantly, whether it is sufficient compared to bi-immunosuppressive therapy (TOF+CNI) in severe MDA5-RP-ILD https://bit.ly/4bEfTpk

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B. Hervier has no potential conflicts of interest to disclose. Y. Uzunhan reports grants from Oxyvie, consulting fees from Boehringer Ingelheim and Pfizer, payment or honoraria for lectures, presentations, manuscript writing or educational events from Sanofi, Boehringer Ingelheim and CSL Vifor, support for attending meetings from Oxyvie and Boehringer Ingelheim, and participation on a data safety monitoring board or advisory board with Boehringer Ingelheim.

Comment on

References

    1. Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology 2020; 95: e70–e78. doi: 10.1212/WNL.0000000000009727 - DOI - PMC - PubMed
    1. Wu W, Guo B, Sun W, et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. Eur Respir J 2025; 65: 2401488. doi: 10.1183/13993003.01488-2024 - DOI - PMC - PubMed
    1. Ida T, Furuta S, Takayama A, et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 2023; 9: e002795. doi: 10.1136/rmdopen-2022-002795 - DOI - PMC - PubMed
    1. So J, So H, Wong VT, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology (Oxford) 2022; 61: 4437–4444. doi: 10.1093/rheumatology/keac094 - DOI - PubMed
    1. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol 2024; 76: 1182–1200. doi: 10.1002/art.42861 - DOI - PMC - PubMed

LinkOut - more resources